(Q24243858)

https://api.crossref.org/works/10.1002%2F14651858.CD001820.PUB3

Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (ESPRIT): randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001820.PUB3

European Stroke Prevention Study. 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001820.PUB3

Dipyridamole: a Controlled Trial of its Effect in Acute Myocardial Infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001820.PUB3

Dipyridamole in chronic stable angina pectoris; a randomized, double blind, placebo-controlled, parallel group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001820.PUB3

Controlled Trial of Dipyridamole in Cerebral Vascular Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001820.PUB3

Veterans Administration Cooperative Study on antiplatelet agents in diabetic patients after amputation for gangrene: II. Effects of aspirin and dipyridamole on atherosclerotic vascular disease rates

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001820.PUB3

Aspirin at any dose above 30 mg offers only modest protection after cerebral ischaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001820.PUB3

Secondary prevention after cerebral ischaemia of presumed arterial origin: is aspirin still the touchstone?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001820.PUB3

Cumulative meta-analysis of aspirin efficacy after cerebral ischaemia of arterial origin

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001820.PUB3

Collaborative overview of randomised trials of antiplatelet therapy--I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001820.PUB3

Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001820.PUB3

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001820.PUB3

The United Kingdom transient ischaemic attack (UK-TIA) aspirin trial: final results

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001820.PUB3

Dipyridamole for preventing stroke and other vascular events in patients with vascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001820.PUB3

Treatment of angina pectoris with dipyridamole: A long-term double blind study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001820.PUB3

7 January 2021

Secondary prevention of stroke

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001820.PUB3

7 January 2021

Frequent reocclusion of patent infarct-related arteries between 4 weeks and 1 year: effects of antiplatelet therapy

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001820.PUB3

7 January 2021

Drug-induced inhibition of platelet function delays progression of peripheral occlusive arterial disease. A prospective double-blind arteriographically controlled trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001820.PUB3

7 January 2021

Persantine-Aspirin Reinfarction Study. Part II. Secondary coronary prevention with persantine and aspirin

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001820.PUB3

7 January 2021

Anti-platelet therapy in graft thrombosis: results of a prospective, randomized, double-blind study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001820.PUB3

7 January 2021

A comparison of two doses of aspirin (30 mg vs. 283 mg a day) in patients after a transient ischemic attack or minor ischemic stroke

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001820.PUB3

7 January 2021

Treatment of angina pectoris with dipyridamole: a double-blind study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001820.PUB3

7 January 2021

Persantine and aspirin in coronary heart disease. The Persantine-Aspirin Reinfarction Study Research Group

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001820.PUB3

7 January 2021

"AICLA" controlled trial of aspirin and dipyridamole in the secondary prevention of athero-thrombotic cerebral ischemia

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001820.PUB3

7 January 2021

Persantine Aspirin Trial in cerebral ischemia. The American-Canadian Co-operative Study Group

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001820.PUB3

7 January 2021

Persantine Aspirin Trial in cerebral ischemia. Part II: Endpoint results. The American-Canadian Co-Operative Study group

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001820.PUB3

7 January 2021

European Stroke Prevention Study. ESPS Group

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001820.PUB3

7 January 2021

10.1002/14651858.CD001820.PUB3

Identifiers

DOI

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

4830599

Fatcat ID

release_32ytilr4o5eb3iwwrjsmlg4cni

0 references

OpenCitations bibliographic resource ID

4830599

1 reference